Quantcast
Last updated on April 17, 2014 at 8:59 EDT

Latest Breast cancer treatment Stories

2014-01-15 08:28:21

Trial Will Compare Investigational Compound's Efficacy and Safety as an Addition to Standard Treatment NORTH CHICAGO, Ill., Jan. 15, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a Phase 3 clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888) when added to carboplatin, a chemotherapy, in women with early-stage, triple-negative breast cancer. The three-arm trial will compare the addition of veliparib plus...

2014-01-14 08:29:36

SAN FRANCISCO, Jan. 14, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that the Independent Data Monitoring Committee (DMC) created to provide safety oversight for the Company's pivotal clinical study for etirinotecan pegol (NKTR-102) has recommended continuation of the BEACON phase 3 trial, based upon the completion of a planned interim efficacy analysis in accordance with the DMC charter. The BEACON trial is evaluating NKTR-102 versus an agent of physician's...

2014-01-06 08:27:53

WORCESTER, Mass. and TORONTO, Jan. 6, 2014 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced the database lock for the primary efficacy analysis of its ongoing AE37 breast cancer vaccine trial. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). A previously released positive interim analysis showed a strong trend toward reduced...

2013-12-27 10:36:56

Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. This is contrary to protocols for larynx cancer, in which a single dose of chemotherapy helps determine which patients fare better with chemotherapy and radiation and which patients should elect for surgery. In larynx cancer, this...

2013-12-14 08:20:06

Fourth Head-to-Head Comparison Reveals Important Clinical Distinctions Between Oncotype DX, the Only Test Demonstrated to Predict Chemotherapy Benefit, and Tests Limited to Breast Cancer Prognosis REDWOOD CITY, Calif., Dec. 14, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from three studies of its Oncotype DX(®) breast cancer test presented at the 36(th) Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), reinforcing the unmatched value of the...

2013-12-13 23:01:59

An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13, 2013 An analysis presented by researchers from the ECOG-ACRIN Cancer Research Group this week at the San Antonio Breast Cancer Symposium showed that stromal tumor-infiltrating lymphocytes (TILs) represent a robust prognostic factor in patients with triple-negative breast cancer (TNBC) who are treated with standard adjuvant...

2013-12-13 13:22:02

New research data presented at the 2013 San Antonio Breast Cancer Symposium New research from University Hospitals (UH) Case Medical Center Seidman Cancer Center and Case Comprehensive Cancer Center at Case Western Reserve University examined how changes in the genetic composition of breast cancer tumors after brief exposure to either biologic therapy or chemotherapy can predict future clinical outcomes in patients. Results showed that through deep genome sequencing, a reduction in the...

2013-12-13 09:38:35

More than one third of younger, early stage breast cancer patients undergo unnecessary imaging procedures – including position emission tomography (PET), computed tomography (CT), nuclear medicine bone scans (NMBS) and tumor markers (TM) -- at the time of staging and diagnosis, according to research from The University of Texas MD Anderson Cancer Center. Presented at a poster session at the 2013 CTRC-AACR San Antonio Breast Cancer Symposium by Carlos Barcenas, M.D., assistant professor...

2013-12-13 09:37:18

A Phase I trial of endoxifen, an active metabolite of the cancer drug tamoxifen, indicates that the experimental drug is safe, with early evidence for anti-tumor activity, a Mayo Clinic study has found. The findings indicate that Z-endoxifen, co-developed by Mayo Clinic Cancer Center and the National Cancer Institute (NCI), may provide a new and better treatment for some women with estrogen positive breast cancer and, in particular, for those women who do not respond to tamoxifen and...

2013-12-13 08:24:57

Combined Safety and Efficacy Results with ThermoDox® plus Hyperthermia for Recurrent Breast Cancer at the Chest Wall LAWRENCEVILLE, N.J., Dec.13, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the presentation of the combined clinical study results from the Company's Phase I DIGNITY study and the Duke University sponsored Phase I trial of ThermoDox® plus hyperthermia in Breast Cancer Recurrences at the Chest Wall...